Background
Sonneratia caseolaris (L.) Engl. (S. caseolaris) belonging to the Sonneratiaceae family is commonly known as Ora. It is traditionally used as an astringent, antiseptic, to treat sprains, swellings, cough and in arresting hemorrhage. The ethanolic extract of S. caseolaris (L.) Engl. fruits was investigated in the present study for its toxicity as well as anti-allergic and anti-hyperglycemic potentials.
Methods
Major phenolic compounds were identified and quantified by HPLC. Behavioral change, body weight, mortality and different blood parameters were measured to assess the toxicological effect of the extract. Anti-allergic activity was evaluated using TDI-induced allergic model mice. Oral glucose tolerance test (OGTT) and STZ-induced diabetic mice were used to evaluate the anti-hyperglycemic activity.
Results
Crude extract contained ellagic acid, vanillic acid and myrecitin (27.41, 3.06 and 7.93 mg per 100 g dry extract respectively). No major toxicity was observed in both acute and sub-acute toxicity study. Oral administration of the extract significantly ameliorated TDI-induced allergic symptoms like sneezing, scratching, swelling, redness and watery rhinorrhoea in the experimental mice. The extracts also reduced the total and differential count of leukocytes in the blood. The extract treated mice showed significant reduction in blood glucose, SGOT, SGPT, cholesterol, triglycerides, urea, creatinine and bilirubin level.
Conclusions
S. caseolaris contains bioactive phytoconstituents which may be the possible precursors to isolate and characterize the novel compounds targeting the diseases like allergy and diabetes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.